These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 32214840)
1. Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics. Lopes GS; Bielinski SJ; Moyer AM; Black Iii JL; Jacobson DJ; Jiang R; Larson NB; St Sauver JL Pharmgenomics Pers Med; 2020; 13():71-79. PubMed ID: 32214840 [TBL] [Abstract][Full Text] [Related]
2. St Sauver JL; Olson JE; Roger VL; Nicholson WT; Black JL; Takahashi PY; Caraballo PJ; Bell EJ; Jacobson DJ; Larson NB; Bielinski SJ Pharmgenomics Pers Med; 2017; 10():217-227. PubMed ID: 28769582 [TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496 [TBL] [Abstract][Full Text] [Related]
4. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics. Zahari Z; Ismail R Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977 [TBL] [Abstract][Full Text] [Related]
5. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery. Rocco R; Thiels CA; Ubl DS; Moyer AM; Habermann EB; Cassivi SD Surgery; 2019 Oct; 166(4):476-482. PubMed ID: 31320226 [TBL] [Abstract][Full Text] [Related]
6. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877 [TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Zhou SF Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987 [TBL] [Abstract][Full Text] [Related]
8. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators. Cavallari LH; Cicali E; Wiisanen K; Fillingim RB; Chakraborty H; Myers RA; Blake KV; Asiyanbola B; Baye JF; Bronson WH; Cook KJ; Elwood EN; Gray CF; Gong Y; Hines L; Kannry J; Kucher N; Lynch S; Nguyen KA; Obeng AO; Pratt VM; Prieto HA; Ramos M; Sadeghpour A; Singh R; Rosenman M; Starostik P; Thomas CD; Tillman E; Dexter PR; Horowitz CR; Orlando LA; Peterson JF; Skaar TC; Van Driest SL; Volpi S; Voora D; Parvataneni HK; Johnson JA; Clin Transl Sci; 2022 Oct; 15(10):2479-2492. PubMed ID: 35899435 [TBL] [Abstract][Full Text] [Related]
12. Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. Zhu Y; Lopes GS; Bielinski SJ; Borah BJ; Larson NB; Moyer AM; Olson JE; Wang L; Weinshilboum R; St Sauver JL Mayo Clin Proc Innov Qual Outcomes; 2021 Feb; 5(1):35-45. PubMed ID: 33718782 [TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Haufroid V; Hantson P Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998 [TBL] [Abstract][Full Text] [Related]
14. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Susce MT; Murray-Carmichael E; de Leon J Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290 [TBL] [Abstract][Full Text] [Related]
15. A consideration of CYP2D6 genetic variations in the Ghanaian population as a potential 'culprit' for the tramadol 'abuse crisis'. Thomford NE; Abraham SA; Nyarko SB; Biney RP BMC Med Genomics; 2024 Jan; 17(1):28. PubMed ID: 38254077 [TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors. Frost DA; Soric MM; Kaiser R; Neugebauer RE Pharmacotherapy; 2019 Jun; 39(6):724-729. PubMed ID: 31038218 [TBL] [Abstract][Full Text] [Related]
18. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia. Ballester P; Muriel J; Peiró AM Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041 [TBL] [Abstract][Full Text] [Related]
19. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Fulton CR; Zang Y; Desta Z; Rosenman MB; Holmes AM; Decker BS; Zhang Y; T Callaghan J; Pratt VM; Levy KD; Gufford BT; Dexter PR; Skaar TC; Eadon MT Pharmacogenomics; 2019 Apr; 20(6):397-408. PubMed ID: 30784356 [No Abstract] [Full Text] [Related]
20. The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Tverdohleb T; Dinc B; Knezevic I; Candido KD; Knezevic NN Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1303-1311. PubMed ID: 27388970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]